Skip to content
Funding & Investment

Isomorphic Labs Raises $5 Billion to Advance AI-Powered Drug Discovery Towards Clinical Trials

Isomorphic Labs raises $5 billion to expand its artificial intelligence-powered drug discovery technology.

Alphabet-backed Isomorphic Labs has raised $5 billion in a Series C funding round to expand its artificial intelligence-powered drug discovery technology and advance potential medicines towards clinical trials. The investment marks a major funding milestone for the biotechnology company as it works to apply advanced AI models to complex biological research.

Announced on November 17, 2026, the funding round was co-led by Greenoaks and Sequoia Capital, with participation from Andreessen Horowitz (a16z) and several other new investors. Alphabet also continued its significant financial backing, while all existing investors participated in the round.

The investment will support the development of Isomorphic Labs' proprietary drug design engine, alongside its growing pipeline of AI-designed therapeutic candidates.

Isomorphic Labs Funding Expands Its AI Drug Discovery Platform

Isomorphic Labs is developing artificial intelligence systems that aim to improve how scientists understand biological processes and design potential medicines.

At the centre of its research is the Isomorphic Drug Design Engine (IsoDDE), a proprietary platform that brings together multiple AI simulation models. According to the company, these models are designed to work across different therapeutic areas and drug modalities, helping researchers investigate complex biological systems and identify promising drug candidates.

The company plans to use the new capital to strengthen its foundational biology models, expand its drug development programmes and build the infrastructure needed to translate AI-generated research into potential treatments.

The investment also supports its internal and partnered medicine candidate pipeline, as Isomorphic Labs works towards progressing its research into clinical development.

Greenoaks and Sequoia Lead $5 Billion Series C Round

The latest financing brings together several major investment firms and existing backers. Greenoaks and Sequoia Capital co-led the round, while Andreessen Horowitz joined as one of the new investors.

Alphabet continued its investment alongside existing supporters, including Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund.

The $5 billion raise follows Isomorphic Labs' $2.1 billion Series B round announced in May 2026, which was led by Thrive Capital. The latest investment represents another substantial financial commitment within approximately six months.

AI Drug Discovery Moves Towards Clinical Development

The funding highlights growing investor interest in applying artificial intelligence to pharmaceutical research, an area where traditional drug development can involve extensive experimentation, substantial costs and lengthy timelines.

AI-powered drug discovery aims to improve parts of this process by helping researchers analyse biological structures, study molecular interactions and identify potential drug candidates.

However, designing a promising molecule is only an early stage of developing a medicine. Candidates must still undergo preclinical research, clinical testing and regulatory review before they can become approved treatments.

Isomorphic Labs has reported positive preclinical progress, but the company has not yet established the effectiveness of its AI-designed medicines through human clinical trials. The new funding is intended to help advance its candidates towards that next stage.

The $5 billion investment places Isomorphic Labs among the most heavily funded companies working at the intersection of artificial intelligence and biotechnology. Its next challenge will be demonstrating that its computational drug-design technology can translate into successful treatments and measurable clinical outcomes.